[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631616":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Johns Hopkins University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LSD + Risperidone","EXPERIMENTAL",null,[13,14],"Drug: LSD","Drug: Risperidone",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","LSD","Participants will be administered LSD followed 45-minutes later by risperidone.",[9],{"type":17,"name":22,"description":19,"armGroupLabels":23,"otherNames":11},"Risperidone",[9],[25],{"name":26,"affiliation":5,"role":27},"Sandeep Nayak, MD","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Matthew Nielsen, BA","CONTACT","917-991-0642","mnielse7@jh.edu",[35],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Johns Hopkins Center for Psychedelic and Consciousness Research","Baltimore","Maryland","21224","United States",{"type":42,"coordinates":43},"Point",[44,45],-76.61219,39.29038,{"lat":45,"lon":44},[48,49],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},{"name":26,"role":27,"phone":11,"phoneExt":11,"email":11},{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100631616",false,"NCT07503002","Shortened LSD Intervention for Major Depressive Disorder","SLIM","Inclusion Criteria:\n\n* Have given written informed consent\n* Meet DSM-5 criteria for MDD\n* MADRS \\>= 28 at screening Can read, write, and speak English fluently\n* Be judged by study team clinicians to be at low risk for suicidality\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing, or not practicing an effective means of birth control\n* Cardiovascular conditions: hypertension with resting blood pressure systolic \\>139 or diastolic \\>89, angina, heart rate \\> 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc \\> 450), TIA in the last 6 months stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy\n* Epilepsy\n* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia\n* Currently taking antipsychotics, or MAO inhibitors\n* Patients taking antidepressant medications and unable to taper\n* Moderate or strong CYP2D6 inhibitor antidepressants must undergo a washout period of 4 weeks or five half-lives prior to treatment\n* Currently taking CYP2D6 inhibitor other than an antidepressant that will be tapered\n* Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UGT1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag\n* Have a seizure disorder, multiple sclerosis, history of significant head trauma, CNS tumor, movement disorders or any neurodegenerative condition\n* Morbidly obese (\\>100 lbs. above ideal body weight, or BMI \\>=40, or BMI \\>=35 with high blood pressure or diabetes)\n* Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal\n* Body weight \\\u003C 45 kg\n* Significant acute adverse reaction (e.g., dystonia) to an antipsychotic\n* Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (including substance-induced), Bipolar I or II Disorder or Major\n* Depression with psychotic features\n* Have a first degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or Bipolar I Disorder.","ALL","21 Years","70 Years",{"count":62,"type":63},10,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.",[69,70,71],"Major Depression Moderate","Major Depression Severe","Major Depression",[18,73,74,75,76,77],"lysergic acid diethylamide","depression","MDD","major depression","major depressive","NOT_YET_RECRUITING","2026-03-30",{"date":81,"type":82},"2026-04-03","ACTUAL",{"date":84,"type":63},"2026-07-01",{"date":86,"type":63},"2027-12-01",{"name":5,"class":6},1]